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Previewsdisparate collection of microbial cues
is unlikely to elicit a uniform response
from the gut. For example, the microbial
structural component polysaccharide
A present on Bacteroides fragilis contrib-
utes to intestinal homeostasis by promot-
ing differentiation of Foxp3+ Treg cells
(Round and Mazmanian, 2010), whereas
segmented filamentous bacterium (SFB)
favors the differentiation of CD4+ T helper
cells into Th17 cells, a more proinflam-
matory phenotype (Ivanov et al., 2009).
Similarly, as reported here and in other
studies, microbial-derived metabolites
(SCFA) also trigger an immune response
from the host. How are these numerous
and disparate microbial cues (structural
products, metabolites, etc.) integrated
into a cohesive and coordinate response
by the host? This dichotomy between
the deleterious and protecting function
of the microbiota and associated microbi-
al products clearly illustrate challenges
facing researchers working on this com-10 Immunity 40, January 16, 2014 ª2014 Elsplex system. Regardless, manipulating
host immune response by altering micro-
bial composition and activities through
dietary intervention and/or specific host
receptors could represent a powerful
mean to promote and/or maintain intes-
tinal homeostasis. Understanding the
various elements implicated in the com-
plex dialog between bacteria and the
host holds much promise for pathologies
such as IBD and CRC.REFERENCES
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The connection between inflammation, autoimmunity, and atherosclerosis is long established. In this issue of
Immunity, Lim et al. (2014) demonstrate that oxidized low-density lipoprotein is one of the key environmental
factors driving the development of inflammatory T helper 17 cells in atherosclerosis.Atherosclerosis is the major culprit in
cardiovascular disease and results from
a complex interaction between a hyper-
cholesterolemic state and chronically
inflamed blood vessels. The contribution
of inflammation to the pathophysiology
of atherosclerosis is well recognized
and became widely accepted after
the 1999 publication of the poignantly
titled ‘‘Atherosclerosis—An Inflammatory
Disease,’’ an influential commentary in
the New England Journal of Medicine by
Ross Russel (Ross, 1999). Indeed, eventhe so-called fatty streaks detected in
infants and children—the first evidence
of vascular injury—are characteristically
inflamed and composed of monocyte-
derived macrophages and T lympho-
cytes. These early and asymptomatic
lesions are mainly lipid-laden macro-
phages (foam cells) with some T cells,
but if the inflammatory response con-
tinues unabated, a mature and complex
plaque rich in activated immune cells will
form and become prone to rupture and
thrombosis (Hansson, 2005). People withautoimmune diseases, such as rheuma-
toid arthritis (RA) and systemic lupus ery-
thematosus (SLE), are significantly more
likely to develop cardiovascular diseases
(Kahlenberg and Kaplan, 2013). Interest-
ingly, elevated CD4+ T helper 17 (Th17)
cells, which produce proinflammatory
interleukin-17A (IL-17A), not only are
associated with these autoimmune dis-
eases but have also been identified in
atherosclerotic lesions (Eid et al., 2009;
Erbel et al., 2009; Hansson, 2005).
Thus, Th17 cells and increased IL-17A
Figure 1. Development of Th17 Cells in the Atherosclerotic Plaque
In the atherosclerotic plaque, oxLDL can activate infiltrating DCs by binding to TLR4 andCD36, resulting in
the production of IL-6. IL-6 enhances Th17 cells to produce IL-17A. IL-17A not only exerts an essential role
in promoting autoimmunity but alsomodifies the atherosclerotic plaque. IL-17A can act on smoothmuscle
cells and endothelial cells to induce proinflammatory cytokines and chemokines, such as CXCL1, which
might enhance the recruitment and activation of myeloid cells. IL-17 can also help stabilize the plaque
through the induction of collagen production from smooth muscle cells. In addition, IL-17 can downregu-
late the expression of VCAM-1 on endothelial cells, thus blocking the infiltration of T cells.
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Previewsproduction might provide additional in-
flammatory links between these diseases.
In this issue of Immunity, Lim et al.
noticed increased expression of IL-17A in
both the aortic sinus and the circulation in
atherosclerotic-prone Ldlr/Apobec1/
(LDb) mice, which have a ‘‘human-like’’
lipid profile and develop mature and
complex plaque on a chow diet (Lim
et al., 2014; Powell-Braxton et al., 1998).
Although there was a moderate but sig-
nificant increase in the frequencies of
IL-17A-producing gd T cells, significant
increases in Th17 cells were detected in
LDb mice (Lim et al., 2014). These results
are consistent with previous reports that
augmented circulating IL-17A and periph-
eral Th17 cell frequency are associated
with atherosclerosis in patients or in
preclinical models (Eid et al., 2009; Erbel
et al., 2009; Gistera˚ et al., 2013; Taleb
et al., 2009). Lim et al. hypothesized that
in vivo atherogenic factors might promote
Th17 cell development. They transferred
myelin oligodendrocyte glycoprotein
(MOG)-specific splenocytes derived from
2D2 transgenic mice into sublethally
irradiated wild-type (WT) and LDb mice
(Lim et al., 2014). The frequencies of
both Th17 and Th1 cells were significantly
higher in the spleens from the LDb recip-
ient mice than in those from the WT mice.By using this elegant system, they demon-
strated that environmental factors other
than dysregulated immune cells in LDb
mice enhanced Th17 cell responses.
Elevated plasma low-density lipoprotein
(LDL) is themajor risk factor for cardiovas-
cular disease and is also evident in LDb
mice (Powell-Braxton et al., 1998). Native
LDL diffuses from the blood into the
innermost layer of the artery, where it is
modified to form oxidized LDL (oxLDL).
Lim et al. showed that the level of oxLDL
was increased in LDb mice. Importantly,
oxLDL, but not native LDL, was able to
enhance Th17 cell differentiation in vitro
when T cells were cocultured with den-
dritic cells (DCs) and stimulated with anti-
CD3, LPS, and TGF-b, whereas Th1 cell
differentiation remained unchanged (Lim
et al., 2014) (Figure 1). Anti-oxLDL admin-
istration in the 2D2 splenocyte transfer
model was able to significantly reduce
the number of Th17 cells while only mildly
affecting the number of Th1 cells. Mecha-
nistically, Lim et al. revealed that oxLDL
can directly act on DCs through oxLDL
receptors, including TLR4 and CD36, to
promote the production of IL-6, which
is critical for Th17 cell differentiation
(Figure 1). Either TLR4- or CD36-deficient
DCs induced significantly less IL-17A pro-
duction from T cells in the previouslyImmunity 4mentioned coculture system in vitro. The
precise mechanism and cellular inter-
actions between oxLDL and leukocytes
within the mature atherosclerotic plaque
are complex and remain unclear partly
because of the lack of precise biochemical
and cellular tools to recapitulate the
modified LDL found in human atheroma.
Nevertheless, the current paper by Lim
et al. adds some clarity around these
processes. They suggest that oxLDL can
promote DC-mediated Th17 cell polariza-
tion by triggering IL-6 production.
Elevated inflammatory cytokines such
as tumor necrosis factor a (TNF-a), IL-
17, and IL-6 in RA and SLE are proposed
to promote premature atherosclerosis
(Kahlenberg and Kaplan, 2013). In this
study, however, Lim and colleagues
proposed that atherosclerosis conditions,
especially with the increased level
oxLDL, could also drive the progression
of autoimmunity through the induction of
Th17 cell development (Lim et al.,
2014). Indeed, upon in vivo challenge of
MOG35–55 peptide in the 2D2 splenocyte
transfer model, the 2D2 transgenic
T cells triggered severe experimental
autoimmune encephalomyelitis (EAE), a
model of human multiple sclerosis, in
LDb recipients compared to in WT recip-
ient mice, and anti-IL-17A treatment alle-
viated the disease severity (Lim et al.,
2014). Although this hypothesis needs to
be further evaluated in other relevant
models of autoimmunity and in human
diseases, the results of Lim et al. shed
new light on the connection between
autoimmune diseases and cardiovascular
diseases.
In addition, this study provides a
chance to reevaluate the antigenic and
atherogenic role of oxLDL in atheroscle-
rosis. Although neutralizing antibodies
to oxLDL have shown to be efficacious
in rodent models of atherosclerosis and
are known to improve insulin resistance
in diet-induced obese primates (Li et al.,
2013), similar approaches in clinical
trials have been disappointing (www.
clinicaltrials.gov ID NCT01258907). The
roles of IL-17A in the development of
atherosclerosis are still controversial.
Although blocking the IL-17A pathway
attenuates the progression of atheroscle-
rosis in some models, a protective role
of the IL-17 pathway, especially in the
stabilization of atherosclerotic plaques,
has also been revealed (Erbel et al.,0, January 16, 2014 ª2014 Elsevier Inc. 11
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Previews2009; Gistera˚ et al., 2013; Taleb et al.,
2009) (Figure 1). Future studies to further
define the functions of IL-17A in human
atherosclerotic diseases and to confirm
the link between oxLDL and the IL-17
pathway will provide novel insight into tar-
geting these pathways for the treatment
of cardiovascular disease.
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